Compare MasterCard Inc (MA) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MasterCard Inc vs Sanofi SA — how do they compare? MasterCard Inc trades at $582.4 (market cap $503.50B), while Sanofi SA trades at $40.27 (market cap $95.18B). The key difference: MasterCard Inc is far larger — about 5.3× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold MasterCard Inc for 134 Days and Sanofi SA for 94 Days on average.
| MA | SNY | |
|---|---|---|
Market Cap | $503.50B | $95.18B |
Volume | 3,390,859 | 2,995,646 |
Sector | Financials | Health |
52-Week High | $599.86 | $52.34 |
52-Week Low | $471.55 | $39.51 |
Typical Hold Time | 134 Days | 94 Days |
Enterprise Value | $516.53B | $114.48B |
Dividend Yield | 0.61% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mastercard (MA) trades at $570.06, up 0.61% with strong technical and fundamental momentum. The stock shows bullish moving average signals and has consistently beaten earnings estimates in recent quarters. Revenue growth accelerated to $32.79B in 2025 with impressive 46.34% net margins, though valuation multiples remain elevated with P/E at 31.61. Recent institutional buying activity and positive analyst coverage support the upward trend.
Mastercard presents a compelling growth story with expanding global payment volumes and digital transformation initiatives. The primary investment thesis centers on continued market share gains and margin expansion, though risks include payment industry disruption from stablecoins and elevated valuation multiples requiring sustained high growth. Analyst consensus targets $666.67 suggest 17% upside potential from current levels.
SNY trades at $40.2, up 1.62% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $46.72B in 2025, and net income improved to $7.81B. Analyst consensus is mixed, with 44% buy ratings. Recent news highlights a major immunology alliance expansion with Regeneron, valued up to $8B, signaling growth initiatives beyond Dupixent.
The outlook for SNY is cautiously optimistic, driven by earnings momentum and strategic partnerships, but faces risks from patent expirations and volatile cash flows. Investment opportunity lies in pipeline diversification and cost management, while investors should monitor competitive pressures and R&D execution. The stock's current valuation metrics suggest reasonable pricing relative to peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MasterCard Inc
Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.
Read more on MA →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
